← Back to screener

Mineralys Therapeutics, Inc. MLYS

Rank #2239 · Nasdaq · $1.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
27.8
P/E
-8.4
P/B
6.22
ROE
-73.7%
Op. Margin
–%
Debt Ratio
-15%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -8.4x, P/B 6.22x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -73.7%. Ranks in the top 92% of the universe.

Safety ★★★★★
Excellent

Debt ratio -15%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2023–$-0.0B$-0.0B$-0.0B–-599
2024–$-0.1B$-0.1B$-0.1B–-581
2025–$-0.2B$-0.2B$0.2B–-15

← See the full screener